Mesalaminedosage
mesalamine 1200 MG Delayed Release Oral Tablet
Dosage and administration
Administration Instructions
Evaluate renal function prior to initiation of mesalamine delayed-release tablets and periodically while on therapy.
Swallow mesalamine delayed-release tablets whole; do not split or crush.
Administer mesalamine delayed-release tablets with food.
Drink an adequate amount of fluids. Adults
The recommended dosage for the induction of remission in adult patients with mildly to moderately active ulcerative colitis is 2.4 g to 4.8 g (two to four 1.2 g tablets) taken once daily.
The recommended dosage for the maintenance of remission is 2.4 g (two 1.2 g tablets) taken once daily. Pediatric Patients The recommended dosage for treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg who can swallow tablets whole is shown in Table 1: Table 1: Recommended Dosage of Mesalamine Delayed-release Tablets for the Treatment of Mildly to Moderately Active Ulcerative Colitis in Pediatric Patients Weighing at least 24 kg Weight of Pediatric Patient Once Daily Mesalamine Delayed-release Tablets Dosage Week 0 to Week 8 After Week 8 24 kg to 35 kg 2.4 g (two 1.2 g tablets) 1.2 g (one 1.2 g tablet) Greater than 35 kg to 50 kg 3.6 g (three 1.2 g tablets) 2.4 g (two 1.2 g tablets) Greater than 50 kg 4.8 g (four 1.2 g tablets) 2.4 g (two 1.2 g tablets) Administration Instructions
Evaluate renal function prior to initiation of mesalamine delayed-release tablets and periodically while on therapy.
Swallow mesalamine delayed-release tablets whole; do not split or crush.
Administer mesalamine delayed-release tablets with food.
Drink an adequate amount of fluids. Recommended Dosage in Adults
For induction of remission: 2.4 g to 4.8 g (two to four 1.2 g tablets) once daily.
For maintenance of remission: 2.4 g (two 1.2 g tablets) once daily. Recommended Dosage in Pediatric Patients
The recommended dosage for treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg who can swallow tablets whole is shown below: Weight of Pediatric Patient Once Daily Mesalamine Delayed-Release Tablets Dosage Week 0 to Week 8 After Week 8 24 kg to 35 kg 2.4 g (two 1.2 g tablets) 1.2 g (one 1.2 g tablet) Greater than 35 kg to 50 kg 3.6 g (three 1.2 g tablets) 2.4 g (two 1.2 g tablets) Greater than 50 kg 4.8 g (four 1.2 g tablets) 2.4 g (two 1.2 g tablets)
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective February 15, 2024. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance